Elizabeth S. Klings, MD
Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Pulmonary, Allergy, Sleep & Critical Care Medicine

MD, New York University School of Medicine
BA, New York University



Dr. Klings is an Associate Professor in the Department of Medicine. She is the Director of the Center for Excellence in Sickle Cell Disease and the Director of the Pulmonary Hypertension at BUSM/Boston Medical Center. She has an outpatient clinical practice focused on patients with pulmonary hypertension and those with pulmonary complications of sickle cell disease. She attends in the Medical Intensive Care Unit and on the Pulmonary Hypertension Consultation Service at Boston Medical Center. As Director of the largest sickle cell center in New England, Dr. Klings has created numerous new clinical programs for our patients and has expanded the clinical trials program.

Dr. Klings’ research since fellowship has focused on pathogenesis of pulmonary vascular complications of sickle cell disease. She is an NIH-funded Principal Investigator .in the Pulmonary Center collaborating with numerous other investigators across the medical campus. She has phenotypically screened over 200 sickle cell patients at Boston Medical Center for the presence of pulmonary hypertension and currently investigating the roles of disease modulators including sleep-disordered breathing and venous thromboembolism in the endothelial and vascular dysfunction these patients experience. Known internationally as a leader in the care and treatment of patients with sickle cell disease, she was first author of the American Thoracic Society sponsored clinical guidelines for Diagnosis and Treatment of Pulmonary Hypertension in Sickle Cell Disease. She recently chaired an ATS sponsored workshop to define clinical and research priorities in sickle cell lung disease and serves on the NHLBI Sickle Cell Disease Advisory Committee.

Diversity, Equity, Inclusion and Accessibility

My commitment to diversity, equity and inclusion dates back to medical school. I came to BU for Internal Medicine Residency training at the then Boston City Hospital to work specifically with an underserved population and was excited by resources that existed here over 20 years ago to improve the healthcare of these patients. During my pulmonary/critical care fellowship, I began to study the pulmonary vascular complications of sickle cell disease. As I joined the faculty in 2000, I began to understand that my work in sickle cell disease coupled exciting science with a population riddled by profound healthcare disparities. I have remained committed to this work since that time. As Director of the Center for Excellence in Sickle Cell Disease, I oversee a diverse group of physicians, advanced practice providers, social workers, patient navigators and research staff dedicated to improving care for our patients.

One of my passions is mentoring trainees and junior faculty, particularly in research. I have over 30 prior and current research mentees, many of whom identify as female or members of under-represented groups. As a member of the LGBTQ+ community, I understand the importance of not only recruiting a diverse group of trainees but assisting them in overcoming barriers to their development.

Within the Pulmonary Center, I serve in two important, and partiaily overlapping, roles. I am the co-chair of our Diversity and Inclusion Faculty Recruitment Committee which has as its goal the identification and recruitment of diverse faculty candidates. Since 2021, I have been the chair of our Racial Equity committee which is leading our division's monthly education sessions on topics of race, health equity, career development and related issues.

Member
Boston University
Pulmonary Center


Program Director
Boston University
Center of Excellence in Sickle Cell Disease


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research




Role of Regional Left Ventricular Strain Patterns in Systemic Sclerosis-related Pulmonary Hypertension
07/01/2023 - 06/30/2026 (Key Person / Mentor)
PI: Justin K. Lui, MD, MS
American Heart Association


Cardiac Strain Phenotyping of Systemic Sclerosis-related Pulmonary Hypertension
04/01/2023 - 03/31/2026 (Key Person / Mentor)
PI: Justin K. Lui, MD, MS
Scleroderma Foundation


Protocol 21427/BAY0903201: ROAR: Riociguat Users Registry
07/13/2021 - 02/28/2024 (PI)
Bayer HealthCare Pharmaceuticals


A StuDy eVAluatiNg the EfficaCy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients
11/30/2018 - 12/31/2023 (PI)
United Therapeutics Corporation


Protocol # STERIO-SCD, A Phase lib Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients with Sickle Cell Diseases
03/20/2018 - 09/19/2023 (Subcontract PI)
University of Pittsburgh Bayer HealthCare


Biomarkers of Left Ventricular Strain in Systemic Sclerosis-related Pulmonary Hypertension
07/27/2022 - 07/27/2023 (Key Person / Mentor)
PI: Justin K. Lui, MD, MS
United Therapeutics Corporation


Protocol #APD811-303: A Study Evaluating the Long-Term Efficacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION
02/06/2019 - 02/06/2023 (PI)
United Therapeutics Corporation


Protocol # 402-C-1602, An Extended Access Program to Assess Long-Term Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension.
07/27/2017 - 07/26/2022 (PI)
Reata Pharmaceuticals, Inc.


Left Ventricular Strain in Systemic Sclerosis-related Pulmonary Hypertension
07/01/2021 - 06/30/2022 (Key Person / Mentor)
PI: Justin K. Lui, MD, MS
NIH/National Heart, Lung, and Blood Institute
1F32HL156614-01

A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Pulmonary Arterial Hypertension
05/30/2014 - 05/31/2022 (PI)
Reata Pharmaceuticals, Inc.


Showing 10 of 35 results. Show All Results

SEG101 (STAND): A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and …
01/23/2020 - 03/01/2028 (PI)
Novartis Pharma Corp

1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCDCARRE Trial)
05/01/2020 - 04/30/2026 (PI)
University of Pittsburgh National Heart, Lung
4UH3HL143192-02

Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)
08/01/2022 - 04/30/2025 (PI)
University of Maryland National Heart, Lung

4202-HEM-301: An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE).
03/24/2021 - 03/23/2025 (PI)
Forma Therapeutics, Inc.

2 U1EMC27864-08-00; Sickle Cell Treatment Demonstration Program
09/01/2021 - 08/31/2024 (PI)
Johns Hopkins University Health Resources and

ASH Research Collaborative-Data Hub Agreement
09/01/2021 - 06/30/2024 (PI)
American Society of Hematology

Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)
05/01/2020 - 07/31/2022 (PI)
University of Pittsburgh National Heart, Lung
4UH3HL143192-02


Title


Yr Title Project-Sub Proj Pubs
2013 Protein biomarkers of pulmonary hypertension in sickle cell disease 5R21HL107993-02 3
2012 Protein biomarkers of pulmonary hypertension in sickle cell disease 1R21HL107993-01A1 3
2011 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-15-5116 259
2010 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-14-6816 259
2009 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-13-6167 259
2009 Gene polymorphism in chronic sickle cell lung disease 5K23HL079003-05 7
2008 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-12-5241 259
2008 Gene polymorphism in chronic sickle cell lung disease 5K23HL079003-04 7
2007 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 2P41RR010888-11-8062 259
2007 Gene polymorphism in chronic sickle cell lung disease 5K23HL079003-03 7
Showing 10 of 17 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Lui JK, Sangani RA, Gillmeyer KR, Vakhshoorzadeh J, Trojanowski MA, Bujor AM, Gopal DM, Wiener RS, LaValley MP, Klings ES. Correction to: Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension. Cardiovasc Drugs Ther. 2024 Jun; 38(3):657.View Related Profiles. PMID: 36662449
     
  2. Siskind SM, Johnson TY, Klings ES, Modzelewski KL. Diabetes Screening Rates and Practices in Patients With Sickle Cell Disease. Diabetes Care. 2024 May 01; 47(5):e42-e43.View Related Profiles. PMID: 38489046
     
  3. Gladwin MT, Gordeuk VR, Desai PC, Minniti C, Novelli EM, Morris CR, Ataga KI, De Castro L, Curtis SA, El Rassi F, Ford HJ, Harrington T, Klings ES, Lanzkron S, Liles D, Little J, Nero A, Smith W, Taylor JG, Baptiste A, Hagar W, Kanter J, Kinzie A, Martin T, Rafique A, Telen MJ, Lalama CM, Kato GJ, Abebe KZ. Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial. Lancet Haematol. 2024 May; 11(5):e345-e357. PMID: 38554715
     
  4. Zheng R, Solomon A, DiLorenzo M, Rajendran I, Park J, Dhongade V, Garcia MA, Eberhardt RT, Sloan JM, Weinberg J, Klings ES. The Association of Anticoagulation Intensity with Outcomes in Hospitalized COVID-19 Patients. Adv Hematol. 2024; 2024:8838308.View Related Profiles. PMID: 38500844; PMCID: PMC10948223; DOI: 10.1155/2024/8838308;
     
  5. Barberà J, Jansa P, Klings E, Ristic A, Keogh A, Solum D, Rao Y, Grover R, Saib I, Sood N. Ralinepag Phase II Open-Label Extension Study in Patients with Pulmonary Arterial Hypertension. Adv Ther. 2024 Mar; 41(3):1062-1074. PMID: 38198043; PMCID: PMC10879237; DOI: 10.1007/s12325-023-02769-7;
     
  6. Lui JK, Cozzolino M, Winburn M, Trojanowski MA, Wiener RS, LaValley MP, Bujor AM, Gopal DM, Klings ES. Role of Left Ventricular Dysfunction in Systemic Sclerosis-Related Pulmonary Hypertension. Chest. 2023 Dec 19.View Related Profiles. PMID: 38128607; DOI: 10.1016/j.chest.2023.12.018;
     
  7. Lui JK, Gillmeyer KR, Sangani RA, Smyth RJ, Gopal DM, Trojanowski MA, Bujor AM, Soylemez Wiener R, LaValley MP, Klings ES. A Clinical Decision Tool for Risk Stratifying Patients with Systemic Sclerosis-Related Pulmonary Hypertension. Lung. 2023 Dec; 201(6):565-569.View Related Profiles. PMID: 37957388; PMCID: PMC11037922; DOI: 10.1007/s00408-023-00646-2;
     
  8. Vakhshoorzadeh J, Lui JK, Sangani RA, Trojanowski MA, Bujor AM, LaValley MP, Klings ES. Emphysema and interstitial lung disease in systemic sclerosis-related pulmonary hypertension. Respir Med. 2023 Sep; 216:107333.View Related Profiles. PMID: 37336329; PMCID: PMC10666733; DOI: 10.1016/j.rmed.2023.107333;
     
  9. Lui JK, Gillmeyer KR, Sangani RA, Smyth RJ, Gopal DM, Trojanowski MA, Bujor AM, Soylemez Wiener R, LaValley MP, Klings ES. A Multimodal Prediction Model for Diagnosing Pulmonary Hypertension in Systemic Sclerosis. Arthritis Care Res (Hoboken). 2023 Jul; 75(7):1462-1468.View Related Profiles. PMID: 35678779; PMCID: PMC9732142; DOI: 10.1002/acr.24969;
     
  10. Lui JK, Sangani RA, Gillmeyer KR, Vakhshoorzadeh J, Trojanowski MA, Bujor AM, Gopal DM, Wiener RS, LaValley MP, Klings ES. Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension. Cardiovasc Drugs Ther. 2024 Jun; 38(3):651-656.View Related Profiles. PMID: 36607535; PMCID: PMC10666735; DOI: 10.1007/s10557-022-07420-1;
     
Showing 10 of 90 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 90 publications over 26 distinct years, with a maximum of 8 publications in 2021

YearPublications
19992
20003
20014
20022
20031
20041
20052
20062
20072
20082
20093
20102
20113
20123
20131
20146
20154
20162
20173
20185
20195
20207
20218
20226
20236
20245
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

anemia, sickle cell
endothelium
pulmonary hypertension

Available to Mentor as: (Review Mentor Role Definitions):
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Diversity Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:

72 E. Concord St
Boston MA 02118
Google Map


Klings's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department